- Home
- MGIC vs CMMB Comparison
MGIC vs CMMB Comparison
Compare MGIC & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGIC | CMMB |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.3M | 13.8M |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | MGIC | CMMB |
|---|---|---|
| Price | $27.24 | $1.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $18.00 | ★ $26.50 |
| AVG Volume (30 Days) | 40.9K | ★ 107.1K |
| Earning Date | 11-18-2025 | 11-20-2025 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 16.15 | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $603,216,000.00 | N/A |
| Revenue This Year | $12.87 | N/A |
| Revenue Next Year | $6.23 | N/A |
| P/E Ratio | $33.41 | ★ N/A |
| Revenue Growth | ★ 12.65 | N/A |
| 52 Week Low | $11.36 | $1.60 |
| 52 Week High | $27.44 | $9.84 |
Technical Indicators
Market Signals| Indicator | MGIC | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 40.68 |
| Support Level | $26.61 | $1.75 |
| Resistance Level | $27.31 | $1.96 |
| Average True Range (ATR) | 0.72 | 0.23 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 94.27 | 44.65 |
Price Performance
Historical ComparisonAbout MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.